Capivasertib China PK Study

Summary

This is an open-label, 2-part Phase I study to assess the PK, safety and tolerability of capivasertib as monotherapy and in combination with paclitaxel in Chinese participants with advanced solid tumours

Timeline

Start

2021-02-22

Primary completion

2022-07-29

Completion

2022-07-29

Publications

• Zhang J, Liu X, Du Y, Mu Y, Meng Y, Sun Y, Zhang L, Chen C, Cullberg M, Fan E, Hu X. A Phase I open-label study to assess the pharmacokinetics, safety, and tolerability of capivasertib alone or in combination with paclitaxel in Chinese patients with advanced solid tumors. BMC Cancer. 2025 Oct 14;25(1):1562. doi: 10.1186/s12885-025-14982-4.

Drugs

Indications